NanoRC

RNA nanotransporter-based therapy for cancer treatment 

Currently, cancer is the second leading cause of death in developed Western countries, after cardiovascular disease. Despite the remarkable advances in the knowledge of the biological mechanisms involved and new therapeutic approaches, the search for treatments with an adequate safety/efficacy balance continues to be one of the main priorities.

The NanoRC project focuses on personalised cancer treatment, modelled on multiple myeloma (MM). To achieve this, personalized specific siRNA will be generated based on the genomic and transcriptomic information of patients. These siRNA will be administered using nanoparticles. Nanotransporters will protect RNA from degradation, specifically target it to tumour cells, and allow for internalisation of the RNA. Once inside the tumour cells, the RNA will specifically bind to its target, exerting the desired therapeutic effect.

Thanks to the collaboration of ADItech in this project, gender has also been considered, taking into account the specific needs of both sexes, which helps achieve the project’s objective more effectively. This work has been made possible thanks to the collaboration of Morteza Mahmoudi of Michigan State University.